Myelofibrosis
Myelofibrosis (MF) is a rare blood cancer that leads to scarring in the bone marrow, which prevents the normal production of blood cells. The condition is a primary subtype of myeloproliferative neoplasms (MPNs) and, in some cases, start as another MPN, like polycythemia vera (PV) or essential thrombocythemia (ET), and later evolve into myelofibrosis.
Hematopoietic stem/progenitor cells from patients with myelofibrosis are “enriched” for a CXCL8/CXCR2 gene signature.
A reduction in spleen volume reduction of ≥35% at 24 weeks occurred in 68% of patients.
The study’s investigators are continuing to monitor overall survival and conduct ongoing patient follow-up.
The overall risk of death from primary myelofibrosis declined by more than 50% after the U.S. FDA approved ruxolitinib.
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
John Mascarenhas, MD, discusses the results of the PACIFICA trial at the 2022 American Society of Hematology Annual Meeting.
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
TP53 and complex karyotype are very high-risk factors in patients with myelofibrosis undergoing HSCT.
The combination of ruxolitinib and pegylated IFNα2a showed significant reductions in spleen length.
BMS-986158 combined with ruxolitinib or fedratinib reduced spleen volume in patients with myelofibrosis.
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
Findings from a new study “underscore the limited therapeutic value of luspatercept” in anemia and myelofibrosis.
Those with MF with high molecular and cytogenetic risk do not benefit from higher intensity conditioning before transplant.
Adding navitoclax to ruxolitinib led to durable spleen volume reductions and improved total symptoms in myelofibrosis.
There are several risk factors for thrombosis and major bleeding in patients with myelofibrosis, according to a recent study.
A large analysis of real-world treatment outcomes in patients with myelofibrosis who were treated with ruxolitinib.
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol.
A recent case study found evidence of an acquired in utero mutation in monozygotic twins who presented with CALR.
A new prognostic model identified risk factors for reduced survival in patients with myelofibrosis who received ruxolitinib.
The EXPAND study supports the use of ruxolitinib 10 mg twice daily in patients with MF.
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application from Cellenkos, Inc. to ...
The REFINE trial observed clinically meaningful splenic responses with navitoclax plus ruxolitinib.
Tasquinimod is an oral immunomodulatory and antiangiogenic investigational treatment.
In patients with persistent or progressive myelofibrosis, adding the BCL-XL/BCL-2 inhibitor navitoclax to therapy with the ...
The FDA has granted accelerated approval to pacritinib for the treatment of adult patients with intermediate or high-risk.
Experts discuss emerging therapeutic targets, the impact of recently approved agents, and incorporating them into practice.
Advertisement
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement